DOP2010000299A - USE OF DRONEDARONA FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY - Google Patents

USE OF DRONEDARONA FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY

Info

Publication number
DOP2010000299A
DOP2010000299A DO2010000299A DO2010000299A DOP2010000299A DO P2010000299 A DOP2010000299 A DO P2010000299A DO 2010000299 A DO2010000299 A DO 2010000299A DO 2010000299 A DO2010000299 A DO 2010000299A DO P2010000299 A DOP2010000299 A DO P2010000299A
Authority
DO
Dominican Republic
Prior art keywords
mortality
prevention
preparation
dronedarona
medicinal product
Prior art date
Application number
DO2010000299A
Other languages
Spanish (es)
Inventor
Christophe Gaudin
Nacera Hamdani
Davide Radzik
Eickels Martin Van
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41278622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2010000299(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0802127A external-priority patent/FR2930148A1/en
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of DOP2010000299A publication Critical patent/DOP2010000299A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Furan Compounds (AREA)

Abstract

Uso de dronedarona o sales farmacéutícamente aceptables de la misma, para la preparación de un medicamento para uso en la prevención de la hospitalización cardiovascular o de Ia mortalidad.Use of dronedarone or pharmaceutically acceptable salts thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or mortality.

DO2010000299A 2008-04-17 2010-10-08 USE OF DRONEDARONA FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY DOP2010000299A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
FR0802127A FR2930148A1 (en) 2008-04-17 2008-04-17 Use of dronedarone to prepare medicament to prevent mortality and/or cardiovascular hospitalizations in patients having e.g. history of atrial fibrillation/atrial flutter, cerebrovascular accident and non-rheumatic valvular heart disease
US4599508P 2008-04-18 2008-04-18
US6025708P 2008-06-10 2008-06-10
FR0803208 2008-06-10
US15161109P 2009-02-11 2009-02-11
US15162209P 2009-02-11 2009-02-11
EP09290095 2009-02-11
EP09290098 2009-02-11
US15995609P 2009-03-13 2009-03-13

Publications (1)

Publication Number Publication Date
DOP2010000299A true DOP2010000299A (en) 2010-11-15

Family

ID=41278622

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000299A DOP2010000299A (en) 2008-04-17 2010-10-08 USE OF DRONEDARONA FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY

Country Status (21)

Country Link
US (8) US8410167B2 (en)
EP (3) EP2280701A2 (en)
JP (1) JP2011518785A (en)
KR (1) KR20100135909A (en)
CN (1) CN102065855A (en)
AR (1) AR072950A1 (en)
AU (1) AU2009252897B2 (en)
CA (1) CA2721489A1 (en)
DO (1) DOP2010000299A (en)
EA (1) EA025017B1 (en)
IL (1) IL208752A0 (en)
MA (1) MA32354B1 (en)
MX (1) MX2010011414A (en)
MY (1) MY153608A (en)
NI (1) NI201000172A (en)
NZ (1) NZ588623A (en)
PE (1) PE20091809A1 (en)
SV (1) SV2010003700A (en)
TW (1) TWI519298B (en)
WO (1) WO2009144550A2 (en)
ZA (1) ZA201007248B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518785A (en) 2008-04-17 2011-06-30 サノフイ−アベンテイス Use of dronedarone to prepare drugs for the prevention of cardiovascular hospitalization or death
FR2930149B1 (en) * 2008-04-17 2011-02-18 Sanofi Aventis ASSOCIATION OF DRONEDARONE WITH AT LEAST ONE DIURETIC, ITS THERAPEUTIC APPLICATION
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
FR2959132A1 (en) * 2010-04-22 2011-10-28 Sanofi Aventis METHODS FOR RISK EVALUATION AND REDUCTION
WO2011135581A2 (en) 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of dronedarone
EP2386300A1 (en) * 2010-05-11 2011-11-16 Sanofi Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter
EP2387996A1 (en) * 2010-05-17 2011-11-23 Sanofi Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients with permanent atrial fibrillation
EP2387997A1 (en) * 2010-05-18 2011-11-23 Sanofi Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients who developed permanent atrial fibrillation throughout the period the dronedarone is administered
AR081392A1 (en) * 2010-05-13 2012-08-29 Sanofi Aventis USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATIONS OR DEATH OR CARDIOVASCULAR EVENTS IN PATIENTS WITH PERMANENT FIBRILATION
WO2012001673A1 (en) * 2010-06-28 2012-01-05 Mapi Pharma Holdings (Cyprus) Limited Amorphous form of dronedarone
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
EP2431033A1 (en) 2010-08-10 2012-03-21 Sanofi Dronedarone for preventing cardiovascular hospitalization or mortality in patients with lone atrial fibrillation
WO2012020377A1 (en) 2010-08-11 2012-02-16 Sanofi Use of dronedarone for the preparation of a medicament for rhythm- and rate-controlling in patients with atrial fibrillation
US20130116586A1 (en) 2011-07-07 2013-05-09 Sanofi Use of dronedarone or a pharmaceutically acceptable salt thereof for the preparation of a drug for the prevention of atrial fibrillation
WO2013024411A1 (en) 2011-08-12 2013-02-21 Lupin Limited Co-milled formulation of dronedarone
JP2021531108A (en) 2018-07-20 2021-11-18 シャークニンジャ オペレーティング エルエルシー Robot Cleaner Debris Removal Docking Station
MA55201A (en) 2019-03-05 2022-01-12 Incyte Corp JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CHRONIC LUNG ALLOGraft DYSFUNCTION
WO2024073499A2 (en) * 2022-09-28 2024-04-04 Bluerock Therapeutics Lp Compositions and methods for treating graft-related arrhythmia

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868179A (en) * 1987-04-22 1989-09-19 Cohn Jay N Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
US4831054A (en) 1988-04-18 1989-05-16 Taro Pharmaceuticals, Ltd. 2-Alkyl-3-benzoylbenzofurans useful for treating cardiac arrhythmia
US4988513A (en) 1990-01-09 1991-01-29 Monsanto Company Method of treating hypokalemia
US4986513A (en) * 1990-05-07 1991-01-22 Harbor Towne Fence, Inc. Fence connector assembly
FR2665444B1 (en) 1990-08-06 1992-11-27 Sanofi Sa AMINO-BENZOFURAN, BENZOTHIOPHENE OR INDOLE DERIVATIVES, THEIR PREPARATION PROCESS AND THE COMPOSITIONS CONTAINING THEM.
FR2735365B1 (en) 1995-06-14 1997-09-05 Sanofi Sa USE OF AN ANGIOTENSIN II ANTAGONIST AND A BENZOFURANE DERIVATIVE FOR THE PREPARATION OF A MEDICAMENT USEFUL IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS
FR2746013B1 (en) * 1996-03-18 1998-05-29 Sanofi Sa USE OF ANTIARRHYTHMIC COMPOUNDS IN THE PREVENTION OF POST INFARCT MORTALITY
FR2760364A1 (en) 1997-03-10 1998-09-11 Sanofi Sa USE OF ANTIARRHYTHMIC COMPOUNDS FOR REDUCING MORTALITY AFTER MYOCARDIAL INFARCTION
US6083991A (en) 1997-06-04 2000-07-04 University Of Florida Research Foundation, Inc. Anti-arrhythmic composition and methods of treatment
FR2764800B1 (en) 1997-06-23 1999-09-10 Sanofi Sa SOLID PHARMACEUTICAL COMPOSITION CONTAINING BENZOFURAN DERIVATIVES
WO1999064050A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel potassium channel drugs and their uses
US6897305B2 (en) 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
PL348198A1 (en) 1998-11-06 2002-05-06 Searle & Co Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
US20030113330A1 (en) 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
US6411840B1 (en) * 1999-11-16 2002-06-25 Cardiac Intelligence Corporation Automated collection and analysis patient care system and method for diagnosing and monitoring the outcomes of atrial fibrillation
FR2803846B1 (en) 2000-01-17 2002-04-05 Clariant France Sa 3- (1-HYDROXY-PENTYLIDENE) -5-NITRO-3H-BENZOFURAN-2-ONE, ITS PREPARATION PROCESS AND ITS USE
GB0020691D0 (en) 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
FR2817864B1 (en) 2000-12-11 2003-02-21 Sanofi Synthelabo METHANESULFONAMIDO-BENZOFURANE DERIVATIVE, ITS PREPARATION METHOD AND ITS USE AS A SYNTHESIS INTERMEDIATE
FR2817865B1 (en) 2000-12-11 2005-02-18 Sanofi Synthelabo AMINOALKOXYBENZOYLE DERIVATIVE IN SALT FORM, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF AS SYNTHESIS INTERMEDIATE
FR2817750B1 (en) 2000-12-11 2003-02-21 Sanofi Synthelabo DRONEDARONE PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION
WO2002051383A2 (en) 2000-12-27 2002-07-04 Genzyme Corporation Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart
IL146389A0 (en) 2001-11-08 2002-07-25 Isp Finetech Ltd Process for the preparation of dronedarone
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
US20030229007A1 (en) 2002-05-30 2003-12-11 Roberto Levi Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia
DE10237819A1 (en) 2002-08-19 2004-03-04 Bayer Ag 5-Nitrobenzofurane
US20050004194A1 (en) 2003-05-15 2005-01-06 Graves Kurt Chum Use of organic compounds
US20060093673A1 (en) 2003-06-27 2006-05-04 Coury Arthur J Controlled release of anti-arrhythmic agents
WO2005014043A1 (en) * 2003-07-16 2005-02-17 Boehringer Ingelheim International Gmbh Chlorthalidone combinations
US7674820B2 (en) 2003-08-07 2010-03-09 Cardiome Pharma Corp. Ion channel modulating activity I
WO2005048979A2 (en) 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
FR2864536B1 (en) 2003-12-24 2006-03-17 Clariant France Sa PROCESS FOR THE PREPARATION OF N-ALKYL-2 (HYDROXY-4-BENZOYL) -3 BENZOFURANES AND INTERMEDIATES FOR CARRYING OUT SAID METHOD
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
US20080234337A1 (en) 2004-08-10 2008-09-25 Ono Pharmaceutical Co., Ltd. Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist
FR2875409B1 (en) 2004-09-17 2010-05-07 Sanofi Aventis PHARMACEUTICAL COMPOSITION COMPRISING A SOLID POLYMERIC MATRIX DISPERSION COMPRISING A CONTINUOUS PHASE OF POLYDEXTROSE AND A CONTINUOUS PHASE OF A POLYMER OTHER THAN POLYDEXTROSE
WO2007009462A2 (en) 2005-07-15 2007-01-25 Region Hovedstaden V/Glostrup Hospital Treatment of migraine and headaches
DE102005046539A1 (en) 2005-09-28 2007-03-29 Anker, Stefan, Prof. Dr. Method of treating cancer- or cachexia patients, using a pacemaker by mitigating the symptoms of shortness of breath, weakness and fatigue; decreasing the weight loss and/or reduction- or removal of muscle loss
US20070248564A1 (en) 2006-04-25 2007-10-25 Roxane Laboratories, Inc. Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia
GB0611210D0 (en) 2006-06-07 2006-07-19 Cambrex Karlskoga Ab Process
CN101153012B (en) 2006-09-29 2010-06-23 北京德众万全药物技术开发有限公司 Novel method of producing dronedarone key intermediate
CN100560067C (en) 2006-09-29 2009-11-18 北京德众万全药物技术开发有限公司 Hydrochloric acid dronedarone medicinal compositions for oral use and preparation method thereof
ITPD20060380A1 (en) 2006-10-12 2008-04-13 Univ Padova USE OF AMIODARONE AND ITS ANALOGUES AS ANTI-VIRAL AGENTS
FR2914644B1 (en) 2007-04-06 2009-06-05 Finorga Soc Par Actions Simpli PROCESS FOR THE PREPARATION OF 2- (N-BUTYL) -3- (4-HYDROXYBENZOYL) -5-NITROBENZOFURAN
FR2915482B1 (en) 2007-04-27 2009-11-27 Finorga PROCESS FOR THE PREPARATION OF 2- (N-BUTYL) -5-NITROBENZOFURANE
WO2008141189A1 (en) 2007-05-09 2008-11-20 Elixir Pharmaceuticals, Inc. Ghrelin modulating compounds and combinations thereof
US20090076137A1 (en) 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched dronedarone
GB0719180D0 (en) 2007-10-02 2007-11-14 Cambrex Karlskoga Ab New process
FR2930148A1 (en) * 2008-04-17 2009-10-23 Sanofi Aventis Sa Use of dronedarone to prepare medicament to prevent mortality and/or cardiovascular hospitalizations in patients having e.g. history of atrial fibrillation/atrial flutter, cerebrovascular accident and non-rheumatic valvular heart disease
FR2930149B1 (en) 2008-04-17 2011-02-18 Sanofi Aventis ASSOCIATION OF DRONEDARONE WITH AT LEAST ONE DIURETIC, ITS THERAPEUTIC APPLICATION
JP2011518785A (en) * 2008-04-17 2011-06-30 サノフイ−アベンテイス Use of dronedarone to prepare drugs for the prevention of cardiovascular hospitalization or death
FR2930150B1 (en) 2008-06-24 2011-01-14 Sanofi Aventis USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR REGULATING THE POTASSIUM RATE IN BLOOD
EP2116239A1 (en) 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
EP2133074A1 (en) 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation
EP2133075A1 (en) 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of cardioversion
EP2153830A1 (en) 2008-08-07 2010-02-17 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of stroke or transient ischemic attack
FR2959132A1 (en) 2010-04-22 2011-10-28 Sanofi Aventis METHODS FOR RISK EVALUATION AND REDUCTION
EP2364703A1 (en) 2010-03-12 2011-09-14 Sanofi Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for administration shortly after amiodarone discontinuation
EP2386300A1 (en) 2010-05-11 2011-11-16 Sanofi Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter
US20120005128A1 (en) 2010-06-29 2012-01-05 Sanofi Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
CN103328983A (en) 2010-12-10 2013-09-25 赛诺菲 Use of dronedarone for the preparation of a drug for use in the management of the risk of liver injury
EP2469281A1 (en) 2010-12-24 2012-06-27 Sanofi Method for managing the risk of liver injury in patients receiving treatment with dronedarone

Also Published As

Publication number Publication date
US20130217763A1 (en) 2013-08-22
CA2721489A1 (en) 2009-12-03
US20100048694A1 (en) 2010-02-25
EP2684564A1 (en) 2014-01-15
NI201000172A (en) 2012-03-15
US20110224293A1 (en) 2011-09-15
EA025017B1 (en) 2016-11-30
US20170273936A1 (en) 2017-09-28
US20150328181A1 (en) 2015-11-19
TW200948354A (en) 2009-12-01
AU2009252897B2 (en) 2015-03-19
KR20100135909A (en) 2010-12-27
IL208752A0 (en) 2010-12-30
CN102065855A (en) 2011-05-18
EP2280701A2 (en) 2011-02-09
MY153608A (en) 2015-02-27
EP3195862A1 (en) 2017-07-26
US20110213027A1 (en) 2011-09-01
US20190046496A1 (en) 2019-02-14
US8410167B2 (en) 2013-04-02
TWI519298B (en) 2016-02-01
US20210267931A1 (en) 2021-09-02
ZA201007248B (en) 2012-07-25
AR072950A1 (en) 2010-10-06
US9107900B2 (en) 2015-08-18
EA201071204A1 (en) 2011-06-30
WO2009144550A3 (en) 2010-02-25
AU2009252897A1 (en) 2009-12-03
SV2010003700A (en) 2011-03-04
NZ588623A (en) 2012-11-30
MA32354B1 (en) 2011-06-01
MX2010011414A (en) 2011-03-15
JP2011518785A (en) 2011-06-30
PE20091809A1 (en) 2009-12-03
WO2009144550A2 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
DOP2010000299A (en) USE OF DRONEDARONA FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY
NI201000211A (en) DRONEDARONE FOR THE PREVENTION OF PERMANENT ATRIAL FIBRILLATION.
CL2012000319A1 (en) Use of a pharmaceutical composition comprising treprostinil for the preparation of a medicament for the treatment or prevention of a condition associated with cystic fibrosis.
CL2014000844A1 (en) Oral pharmaceutical formulation of prolonged release in the form of multiparticles, comprising a) 40-o- (2-hydroxy) ethyl-rapamycin and b) at least one prolonged-release coating.
WO2012156296A8 (en) Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients
BRPI1009392A2 (en) "pharmaceutical formulation, and use of a pharmaceutically effective amount of a pharmaceutical formulation."
AR082493A1 (en) FORMULATIONS BASED ON NALBUFINE, AND ITS USES
ECSP11010811A (en) USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION OF ICTUS OR TRANSITIONAL ISCHEMICAL ATTACK
CY1121852T1 (en) FORMULATIONS AND METHODS OF PREPARING FORMULATIONS FOR USE IN COLON CLEANSING
EA200900958A1 (en) DRUG NEVIRAPIN PREPARATION
ECSP10010553A (en) USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THIS, FOR THE PREPARATION OF A MEDICINAL PRODUCT TO REGULATE THE LEVEL OF POTASSIUM IN THE BLOOD
NI201000212A (en) DRONEDARONE FOR THE PREVENTION OF CARDIOVERSION.
BRPI0920878A2 (en) ksp161 inhibitor to increase apoptosis, its administration and its use.
ECSP10010540A (en) USE OF DRONEDARONA FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY
CR11721A (en) USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY
AR081031A1 (en) USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY IN PA-HUNDREDS WHO HAVE A FIRST RECURRENCE OF HEADPHONES OR ALE-TEO HEADPHONES
AR084975A1 (en) USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY IN PATIENTS WITH ISOLATED HEADPHONES FIBRILATION
TN2010000454A1 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalisation or of mortatily
CL2009000920A1 (en) Use of dronedarone or a pharmaceutically acceptable salt to prepare a drug useful for the prevention of cardiovascular hospitalizations.
AR081392A1 (en) USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATIONS OR DEATH OR CARDIOVASCULAR EVENTS IN PATIENTS WITH PERMANENT FIBRILATION
UA105513C2 (en) Glucosamine prolonged release dosage form
TR201005911A2 (en) A drug formulation with improved dissolution profile.
RU2011145777A (en) MEDICINAL PREPARATION FOR ANTI-INFLAMMATORY ANTI-INFLAMMATORY ACTIVITY
TH111755B (en) Triazolopiridazine as PAR 1 inhibitors, their preparations and their use as drugs.
TR200805337A2 (en) New oral pharmaceutical formulations containing the active ingredient Valsartan